NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · Real-Time Price · USD
2.350
0.00 (0.00%)
May 1, 2025, 4:00 PM EDT - Market closed
Company Description
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome.
It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.
NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
NeurAxis, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Aug 9, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Brian Carrico |
Contact Details
Address: 11611 North Meridian St, Suite 330 Carmel, Indiana 46032 United States | |
| Phone | 812 689 0791 |
| Website | neuraxis.com |
Stock Details
| Ticker Symbol | NRXS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001933567 |
| CUSIP Number | 64134X201 |
| ISIN Number | US64134X2018 |
| Employer ID | 45-5079684 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Brian Carrico | President, Chief Executive Officer and Director |
| Timothy Robert Henrichs | Chief Financial Officer |
| Dr. Adrian Miranda | Senior Vice President of Science and Technology and Chief Medical Officer |
| Dr. Thomas Carrico | Chief Regulatory Officer and Compliance and Privacy Officer |
| Dr. Christopher Robin Brown D.D.S. | Founder, Director of Innovation and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | ARS | Filing |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | 424B3 | Prospectus |
| Feb 11, 2025 | EFFECT | Notice of Effectiveness |
| Feb 5, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 20, 2024 | UPLOAD | Filing |